IXICO plc announced that an existing client has contracted IXICO to provide imaging services for the extension study of their Huntington's disease ('HD') Ph2b trial. This is a new study protocol and results in a new work order worth just under £2 million which IXICO expects to deliver over the next 4 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.875 GBX | 0.00% |
|
-1.79% | -45.00% |
May. 23 | Ixico wins deal; United Oil & Gas settles debt | AN |
May. 23 | IXICO plc Signs Contract with Global Alzheimer's Platform Foundation to Support Bio-Hermes 2 Trial | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.00% | 4.22M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces Contract Win in Huntington's Disease